白雲山(00874.HK)子公司擬與興證資管簽訂基礎資產買賣協議
白雲山(00874.HK)公布,董事會今日(22日)通過關於子公司廣州醫藥開展應收賬款資產證券化業務的議案。
據此,廣州醫藥作為賣方及原始權益人擬與興證資管簽訂基礎資產買賣協議,向興證資管出售基礎資產,而興證資管作為買方同意根據基礎資產買賣協議的條款購買基礎資產並設立專項計劃發行總額不超過30億元人民幣的資產支持證券,同時亦擔任專項計劃的管理人。興證資管將在上交所批准上述發行之日起計算的兩年內分期發行專項計劃,每期專項計劃的存續期不超過兩年。
公司指,廣州醫藥通過本次交易利用應收賬款進行資產證券化,可以將應收賬款轉變為流動性較高的現金資產,達到盤活資產存量的目的。從本次交易所得款項擬用於補充廣州醫藥的流動資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.